Table 5. Tumor molecular analysis.

Tumor Molecular Aberration	N/Total tested (%)	Cancer Type	Best Response Comments
PIK3CA (C378F)	1/14 (7%)	Cholangiocarcinoma	26% increase
PTEN (R173C)	1/14 (7%)	Cervical cancer	NE; off study for grade 3 headache after first bevacizumab infusion
PTEN (R335*)	1/14 (7%)	HNSCC	NE; off study for grade 3 infusion reaction during first cetuximab infusion
PTEN loss	1/14 (7%)	HNSCC	23% decrease
HRAS (Q61R)	1/14 (7%)	Urethral carcinoma	95% increase

Abbreviation: N, number of patients; NE, no response evaluation; HNSCC, squamous cell carcinoma of the head and neck; IHC, immunohistochemistry